Altogether, the phase‐specific functionality of SIRT1 in disease stages underscores the importance of optimizing the timing of SIRT1‐targeted therapies to maximize clinical benefits in COVID‐19 progression management [9, 42, 81, 82]. The gene discussed is SIRT1; the disease is COVID-19.